Strs Ohio Sells 3,832 Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH)

Share on StockTwits

Strs Ohio decreased its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 27.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,951 shares of the medical equipment provider’s stock after selling 3,832 shares during the quarter. Strs Ohio’s holdings in Zimmer Biomet were worth $1,171,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Lindbrook Capital LLC raised its holdings in Zimmer Biomet by 207.6% during the 1st quarter. Lindbrook Capital LLC now owns 203 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 137 shares during the last quarter. Motco raised its holdings in Zimmer Biomet by 86.2% during the 1st quarter. Motco now owns 216 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 100 shares during the last quarter. Horan Capital Advisors LLC. bought a new position in Zimmer Biomet during the 1st quarter worth approximately $51,000. FNY Investment Advisers LLC bought a new position in Zimmer Biomet during the 1st quarter worth approximately $54,000. Finally, Quantamental Technologies LLC bought a new stake in shares of Zimmer Biomet in the 1st quarter valued at $69,000. Hedge funds and other institutional investors own 87.89% of the company’s stock.

Shares of ZBH stock opened at $138.17 on Wednesday. The company has a market cap of $28.40 billion, a price-to-earnings ratio of 18.09, a PEG ratio of 2.47 and a beta of 1.15. The company’s fifty day simple moving average is $126.39. The company has a quick ratio of 0.56, a current ratio of 1.19 and a debt-to-equity ratio of 0.58. Zimmer Biomet Holdings Inc has a 12 month low of $96.99 and a 12 month high of $140.53.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Friday, July 26th. The medical equipment provider reported $1.93 EPS for the quarter, beating the Zacks’ consensus estimate of $1.91 by $0.02. The business had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.98 billion. Zimmer Biomet had a negative net margin of 4.56% and a positive return on equity of 13.40%. Zimmer Biomet’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.92 EPS. Research analysts anticipate that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th were paid a dividend of $0.24 per share. The ex-dividend date was Thursday, June 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.69%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 12.57%.

Several analysts have recently weighed in on ZBH shares. Citigroup lifted their price objective on shares of Zimmer Biomet from $146.00 to $158.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Cantor Fitzgerald set a $135.00 price objective on shares of Zimmer Biomet and gave the company a “buy” rating in a research note on Friday, April 26th. TheStreet lowered shares of Zimmer Biomet from a “b-” rating to a “c” rating in a research note on Friday, June 7th. Wells Fargo & Co lifted their price objective on shares of Zimmer Biomet from $143.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, July 29th. Finally, Oppenheimer lifted their price objective on shares of Zimmer Biomet from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, July 29th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $141.56.

In other Zimmer Biomet news, insider Sang Yi sold 426 shares of the business’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $114.88, for a total transaction of $48,938.88. Following the completion of the sale, the insider now owns 1,457 shares in the company, valued at approximately $167,380.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.72% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: How can you know how many shares are floating?

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

BRAINSWAY LTD/S  Lowered to “Sell” at Zacks Investment Research
BRAINSWAY LTD/S Lowered to “Sell” at Zacks Investment Research
Sierra Bancorp  Upgraded at Zacks Investment Research
Sierra Bancorp Upgraded at Zacks Investment Research
Zacks Investment Research Upgrades Bank of Commerce  to “Hold”
Zacks Investment Research Upgrades Bank of Commerce to “Hold”
bluebird bio  Upgraded at BidaskClub
bluebird bio Upgraded at BidaskClub
Bloomin’ Brands  Upgraded to “Hold” at ValuEngine
Bloomin’ Brands Upgraded to “Hold” at ValuEngine
Blackbaud  Upgraded by ValuEngine to Strong-Buy
Blackbaud Upgraded by ValuEngine to Strong-Buy


© 2006-2019 Ticker Report